Aleteia logoAleteia logoAleteia
Friday 26 April |
Our Lady of Good Counsel
Aleteia logo
Lifestyle
separateurCreated with Sketch.

The billionaire pharmaceutical CEO who’s “not interested in money”

STEPHANE-BANCEL-MODERNA-000_8VD2E8.jpg

HANDOUT | MODERNA | AFP

Stéphane Bancel.

Agnès Pinard Legry - published on 11/13/21

The CEO of Moderna says that he plans to give most of his fortune to nonprofits or charities.

As the CEO of Moderna, one of the laboratories that developed a vaccine against SARS-CoV-2, Frenchman Stéphane Bancel has seen his fortune grow from $460 million to $10.7 billion, according to the Bloomberg Billionaires Index.

In an interview with Le Parisien, he said he does not intend to leave this amount entirely to his children. “My wife and I intend to give them the essentials … We told them, ‘We’re paying for your education, and we’ll bequeath you a family home, then it’s up to you to manage.’”

“Today, we already support about 10 associations, committed to health, inequality, and education. My wife having been adopted, these themes are very close to her heart, as well as mine,” says Bancel. “We help former American prisoners to reintegrate, and we support an association in Haiti. I’ve never been interested in money.”

Originally from Marseille, Bancel began his career in marketing at the Lyon-based laboratory BioMérieux. “After Harvard, all my classmates chose to pursue a career in IT, where they were sure to make money quickly, but I took a risk and went into healthcare,” he said. “I always wanted to provide a home for my family, to feed them, but my ambition was never to collect houses, cars or boats.”

Tags:
Information about the vaccine against COVID-19
Enjoying your time on Aleteia?

Articles like these are sponsored free for every Catholic through the support of generous readers just like you.

Help us continue to bring the Gospel to people everywhere through uplifting Catholic news, stories, spirituality, and more.

Aleteia-Pilgrimage-300×250-1.png
Daily prayer
And today we celebrate...




Top 10
See More
Newsletter
Get Aleteia delivered to your inbox. Subscribe here.